U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07450521) titled 'Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males' on Feb. 10.
Brief Summary: A randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, and PK of MTX-463 when administered via SC injection in healthy adult males.
Study Start Date: Feb. 18
Study Type: INTERVENTIONAL
Condition:
Healthy Adult Male
Intervention:
BIOLOGICAL: MTX-463
MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases...